Get the Stockscreener App
5.60
1.06%
-0.06
After Hours:
5.60
Voyager Therapeutics Inc stock is traded at $5.60, with a volume of 169.19K.
It is down -1.06% in the last 24 hours and down -6.98% over the past month.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
See More
Previous Close:
$5.66
Open:
$5.68
24h Volume:
169.19K
Relative Volume:
0.38
Market Cap:
$305.90M
Revenue:
$163.78M
Net Income/Loss:
$25.88M
P/E Ratio:
8.6154
EPS:
0.65
Net Cash Flow:
$-28.66M
1W Performance:
-0.18%
1M Performance:
-6.98%
6M Performance:
-31.62%
1Y Performance:
-24.02%
1-Day Range:
$5.585
$5.73
1-Week Range:
$5.16
$5.775
52-Week Range:
$4.99
$10.66
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Name
Voyager Therapeutics Inc
Sector
Industry
Phone
857-259-5340
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
5.60 | 305.90M | 163.78M | 25.88M | -28.66M | 0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-02-24 | Initiated | Citigroup | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Oct-16-24 | Initiated | Leerink Partners | Outperform |
| Mar-26-24 | Initiated | Guggenheim | Buy |
| Mar-19-24 | Initiated | H.C. Wainwright | Buy |
| Mar-07-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-10-23 | Initiated | Truist | Buy |
| Mar-10-23 | Initiated | Oppenheimer | Outperform |
| Oct-07-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-03-21 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-03-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-24-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-23-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-10-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-19-20 | Initiated | The Benchmark Company | Buy |
| Feb-06-20 | Initiated | Oppenheimer | Outperform |
| Nov-15-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Sep-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-18 | Initiated | H.C. Wainwright | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-12-18 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-02-18 | Initiated | Morgan Stanley | Overweight |
| Nov-28-17 | Resumed | Piper Jaffray | Overweight |
| Oct-31-17 | Initiated | Robert W. Baird | Outperform |
| Oct-27-17 | Initiated | Canaccord Genuity | Buy |
| Oct-23-17 | Reiterated | Stifel | Buy |
| Oct-12-17 | Initiated | Raymond James | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-28-17 | Resumed | Stifel | Buy |
View All
Voyager Therapeutics Inc Stock (VYGR) Latest News
Voyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences Conference - GlobeNewswire
Neurogenetic Medicine Pioneer Voyager Sets Stage for Major Healthcare Conference Appearance - StockTitan
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of “Buy” from Analysts - Defense World
Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance (VYGR) - Seeking Alpha
What Makes Voyager Therapeutics (VYGR) a New Buy Stock - Yahoo Finance
(VYGR) On The My Stocks Page - Stock Traders Daily
Voyager Therapeutics (NASDAQ:VYGR) Given “Buy” Rating at HC Wainwright - Defense World
H.C. Wainwright maintains $30 target on Voyager Therapeutics stock - Investing.com India
HC Wainwright Reiterates "Buy" Rating for Voyager Therapeutics (NASDAQ:VYGR) - MarketBeat
Reviewing Voyager Therapeutics (NASDAQ:VYGR) and Kyverna Therapeutics (NASDAQ:KYTX) - Defense World
Q1 Earnings Estimate for VYGR Issued By Leerink Partnrs - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock Position Lowered by JPMorgan Chase & Co. - Defense World
Analysts Issue Forecasts for VYGR FY2025 Earnings - Defense World
Wedbush assumes coverage of Voyager with outperform rating - MSN
Cantor Fitzgerald Comments on VYGR FY2025 Earnings - MarketBeat
Voyager Therapeutics up 8% following quarterly beats - MSN
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - Yahoo Finance
Barclays PLC Grows Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Insider Sell: Robin Swartz Sells Shares of Voyager Therapeutics Inc - GuruFocus.com
Voyager Therapeutics chief scientific officer sells shares worth $6,109 By Investing.com - Investing.com Canada
Voyager Therapeutics COO Robin Swartz sells $15,712 in stock By Investing.com - Investing.com South Africa
Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Sells $15,712.83 in Stock - MarketBeat
Voyager Therapeutics chief scientific officer sells shares worth $6,109 - Investing.com
Cantor Fitzgerald Predicts VYGR FY2024 Earnings - Defense World
Analysts Issue Forecasts for VYGR FY2024 Earnings - MarketBeat
Even though Voyager Therapeutics (NASDAQ:VYGR) has lost US$40m market cap in last 7 days, shareholders are still up 80% over 3 years - Simply Wall St
Voyager Therapeutics stock hits 52-week low at $5.18 By Investing.com - Investing.com Canada
Voyager Therapeutics stock hits 52-week low at $5.18 - Investing.com India
Cantor Fitzgerald Begins Coverage on Voyager Therapeutics (NASDAQ:VYGR) - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Rating of “Buy” by Brokerages - Defense World
Cantor Fitzgerald Initiates Coverage of Voyager Therapeutics (VYGR) with Overweight Recommendation - MSN
Voyager Therapeutics (NASDAQ:VYGR) Coverage Initiated by Analysts at Cantor Fitzgerald - MarketBeat
Trend Tracker for (VYGR) - Stock Traders Daily
Jane Street Group LLC Lowers Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Jane Street Group LLC Cuts Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - MarketBeat
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Purchased by Geode Capital Management LLC - Defense World
Barclays PLC Boosts Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by State Street Corp - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Position Reduced by State Street Corp - MarketBeat
Voyager Therapeutics, Inc. (VYGR): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance
How to Take Advantage of moves in (VYGR) - Stock Traders Daily
Voyager Therapeutics COO Robin Swartz sells shares worth $36,725 By Investing.com - Investing.com Australia
Voyager Therapeutics COO Robin Swartz sells shares worth $36,725 - Investing.com India
Robin Swartz Sells 6,500 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock - MarketBeat
Insider Sell: Robin Swartz Sells 6,500 Shares of Voyager Therape - GuruFocus.com
Should Weakness in Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - Simply Wall St
Voyager Therapeutics Inc Stock (VYGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):